MBOT
NASDAQMicrobot Medical Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Website
News25/Ratings2
News · 26 weeks560%
2025-10-262026-04-19
Mix4290d
- SEC Filings17(40%)
- Other14(33%)
- Insider10(24%)
- Analyst1(2%)
Latest news
25 items- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and Improve Ergonomic Issues Impacting Health Practitioners HINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today highlighted that the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), recently released up
- PRMicrobot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare ConferenceHINGHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will highlight recent commercial achievements leading to the recent Full Market Release (FMR) of the LIBERTY System at the 25th Annual Needham Virtual Healthcare Conference, being held April 13-16th. Harel Gadot, CEO, President & Chairman of Microbot Medical, will be presenting live at 10:15 a.m. ET on Wednesday, April 15, 2026. Mr. Gadot, along with other of Microbot's senior executives, will provide an overview of the Company and its strategic positioning, growth opportunities, and ability to address ma
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific MeetingHINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has successfully executed its limited market release (LMR) and will commence its full market release (FMR) in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks, including globally recognized hospitals such as Emory Healthcare and Tampa General Hospital. Microbot considers this achievement a reflection of the highly effective execution of the LIBERTY System's LMR and positions the Company to commence the FMR of the LIBERTY
- SECSEC Form 424B5 filed by Microbot Medical Inc.424B5 - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- INSIDERSEC Form 4 filed by Madden Martin J.4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Stockburger Aileen Ptucha4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Wenderow Tal Baruch4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Wilson David James4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Burell Scott R4 - Microbot Medical Inc. (0000883975) (Issuer)
- INSIDERSEC Form 4 filed by Laxminarain Prattipati4 - Microbot Medical Inc. (0000883975) (Issuer)
- PRMedTech's Edge: How AI and Remote Diagnostics Drive Scalable ValueIssued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac
- SECSEC Form 10-K filed by Microbot Medical Inc.10-K - Microbot Medical Inc. (0000883975) (Filer)
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PREmory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®'s LIBERTY® Endovascular Robotic SystemWorld's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types ATLANTA and HINGHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Emory Healthcare has successfully completed robotic peripheral endovascular procedures — minimally invasive treatments for certain vascular conditions — using Microbot Medical's (NASDAQ:MBOT) LIBERTY® Endovascular Robotic System. Microbot believes that the application of the single-use robotic system can expand patient access to high-quality care. Emory
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal Study in Leading Peer-Reviewed Medical JournalBeing Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the Study Company Remains Focused on Expanding Evidence-Based Data to Support Broader Commercial Adoption of the LIBERTY System HINGHAM, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, which is already garnering medical and industry attention, today announced the publication of an article in the Journal of Vascular and Interventional Radiology (JVIR), titled "In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Per
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® to Participate at the 38th Annual Roth ConferenceHINGHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23rd. Mr. Gadot will highlight the Company's recent achievements, and how LIBERTY is
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)
- PRMicrobot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First TimeHINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first time the Company has been invited to participate in this conference, reflecting growing market interest in the Company. Harel Gadot, CEO, President & Chairman will present live at 8:40 am ET on Thursday, March 19th. Mr. Gadot will highlight recent achievements from LIBERTY's limited market release and review key market growth drivers that the Company believes
- SECMicrobot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Microbot Medical Inc. (0000883975) (Filer)